title: Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.
abstract: BACKGROUND
  Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT.
  
  
  METHODS
  Two clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay.
  
  
  RESULTS
  In both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana.
  
  
  CONCLUSIONS
  Immunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy.
  
  
  BACKGROUND
  ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007).
authors.affiliation: Centre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
authors.forename: Panchali
authors.initials: P
authors.lastname: Roy Chowdhury
authors.affiliation: Centre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Meier
authors.affiliation: Centre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
authors.forename: Hewad
authors.initials: H
authors.lastname: Laraway
authors.affiliation: Meningitis Vaccine Project, PATH, Seattle, Washington.
authors.forename: Yuxiao
authors.initials: Y
authors.lastname: Tang
authors.affiliation: Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
authors.forename: Abraham
authors.initials: A
authors.lastname: Hodgson
authors.affiliation: Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
authors.forename: Samba O
authors.initials: SO
authors.lastname: Sow
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Godwin C
authors.initials: GC
authors.lastname: Enwere
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Brian D
authors.initials: BD
authors.lastname: Plikaytis
authors.affiliation: Serum Institute of India Limited, Pune.
authors.forename: Prasad S
authors.initials: PS
authors.lastname: Kulkarni
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Preziosi
authors.affiliation: Centre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Niedrig
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D005869:Ghana; D064368:Healthy Volunteers; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D008302:Mali; D008458:Measles Vaccine / Q000008:administration & dosage; D022401:Meningococcal Vaccines / Q000008:administration & dosage*; D009500:Neutralization Tests; D022341:Yellow Fever Vaccine / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D008458:Measles Vaccine; C573970:MenAfriVac; D022401:Meningococcal Vaccines; D022341:Yellow Fever Vaccine
keywords: Africa; coadministration; group A meningococcal conjugate vaccine; microneutralization assay; yellow fever vaccine